Piggybacking off an earlier deal, Bristol-Myers Squibb ($BMY) has signed another manufacturing agreement with South Korean giant Samsung. The new project tasks Samsung with making "commercial drug substances and drug product" for a slew of Bristol's biologics, part of the drugmaker's global expansion efforts. News